Technical Articles

重组人il-12 r beta 1蛋白在三条成药路线里为什么都要被验证?从 p40、p19 到受体侧
Why Three Drug-Development Routes All Validate Through IL-12 R beta 1: From p40 and p19 to the Receptor Side
发布时间 2026-11-18
p40 blockers, p19-selective IL-23 inhibitors and receptor-side programs all converge on IL-12Rβ1 engagement assays. This article traces the validation chain.
View details
  • Immunity/Inflamma
  • IL-12 R beta 1
  • IL-23
  • p40
  • p19
  • drug development
  • target validation
  • UA010373
重组人il-12 r beta 1蛋白做包被与结合怎么控变量?六个动作与两种价态的读数差别
Coating and Binding with IL-12 R beta 1: Six Moves, Two Valence States and How the Readout Differs
发布时间 2026-11-18
A controlled comparison of IL-12Rβ1 coating versus capture setups: His-tag orientation, monovalent versus bivalent presentation and how each changes the readout.
View details
  • Immunity/Inflamma
  • IL-12 R beta 1 coating
  • His tag
  • valence
  • binding assay
  • blocking
  • ELISA
  • UA010373
重组人il-12 r beta 1蛋白为什么是共用门?两个配体与两条信号在这里分岔
Why IL-12 R beta 1 Acts as a Shared Gate: Two Ligands and Two Signals Diverge Here
发布时间 2026-11-18
IL-12Rβ1 binds the shared p40 subunit of IL-12 and IL-23, then hands each complex to a different second chain. This article maps the gate and the divergence.
View details
  • Immunity/Inflamma
  • IL-12 R beta 1
  • CD212
  • IL-12 receptor
  • IL-23 receptor
  • p40
  • STAT4
  • STAT3
  • UA010373
Total 3
  • 1
Go to